UBS Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its price target lowered by equities researchers at UBS Group from $200.00 to $195.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price target points to a potential upside of 47.54% from the stock’s previous close.

Other analysts have also issued research reports about the company. Wells Fargo & Company decreased their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group boosted their price target on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. Finally, KeyCorp reissued an “overweight” rating on shares of Repligen in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Down 1.9%

NASDAQ RGEN traded down $2.51 during midday trading on Wednesday, hitting $132.17. 893,531 shares of the company traded hands, compared to its average volume of 769,279. The company has a market cap of $7.44 billion, a PE ratio of 6,606.20, a price-to-earnings-growth ratio of 2.47 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. Repligen has a 52 week low of $102.96 and a 52 week high of $175.77. The company’s 50-day simple moving average is $155.83 and its 200-day simple moving average is $146.87.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the company posted $0.44 earnings per share. The firm’s revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, equities research analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. MidFirst Bank bought a new stake in shares of Repligen during the 4th quarter valued at about $299,000. Pacer Advisors Inc. grew its position in shares of Repligen by 2.5% during the 4th quarter. Pacer Advisors Inc. now owns 10,469 shares of the biotechnology company’s stock worth $1,715,000 after buying an additional 256 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Repligen by 12.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock valued at $105,874,000 after acquiring an additional 74,044 shares in the last quarter. Compound Planning Inc. acquired a new position in shares of Repligen during the 4th quarter valued at $204,000. Finally, Invesco Ltd. boosted its stake in Repligen by 43.9% during the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after acquiring an additional 383,399 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

More Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q4 beat: Repligen reported $0.49 EPS vs. $0.44 expected and $197.9M revenue (+18% Y/Y), with management highlighting solid organic growth and improving margins. Article Title
• Neutral Sentiment: Mixed analyst views on valuation vs. growth: TD Cowen maintained a Buy and $200 PT, signaling continued conviction in long-term upside. Article Title
• Neutral Sentiment: Canaccord Genuity reiterated a Hold and $165 PT, noting solid execution but limited near-term upside at current valuation. Article Title
• Negative Sentiment: Conservative FY2026 guidance: Repligen set EPS guidance of $1.93–$2.01 and revenue $810–$840M, below consensus — investors typically punish guidance that implies slower near‑term growth. Article Title
• Negative Sentiment: Barclays trimmed its price target from $200 to $175 (keeps an Overweight rating), reducing upside expectations and likely contributing to selling pressure. Article Title
• Negative Sentiment: Wells Fargo lowered its target from $190 to $180 while maintaining Overweight, another near‑term negative signal for sentiment. Article Title

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.